Spots Global Cancer Trial Database for intravenous
Every month we try and update this database with for intravenous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | NCT00001499 | Carcinoma, Non-... Lung Neoplasms | paclitaxel cisplatin chest radiother... | - | National Institutes of Health Clinical Center (CC) | |
| Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor | NCT02813044 | Pituitary Tumor | total intraveno... inhalation anes... | 19 Years - | Yonsei University | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor | NCT02813044 | Pituitary Tumor | total intraveno... inhalation anes... | 19 Years - | Yonsei University | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | NCT00035100 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | epothilone b | 18 Years - | Novartis | |
| Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer | NCT00091611 | Kidney Neoplasm... | IL-2 (interleuk... OKT3 Cyclophosphamid... Fludarabine Mesna | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00401765 | Prostatic Neopl... | CNTO 328 Docetaxel | 18 Years - | Centocor, Inc. | |
| EPO906 Therapy in Patients With Advanced Melanoma | NCT00035165 | Melanoma | epothilone b | 18 Years - 85 Years | Novartis | |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | NCT00402181 | Multiple Myelom... | Siltuximab Dexamethasone | 18 Years - | Centocor, Inc. | |
| EPO906 Therapy in Patients With Prostate Cancer | NCT00035113 | Prostatic Neopl... | epothilone b | 18 Years - 85 Years | Novartis | |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | NCT05592626 | Advanced Solid ... Genital Neoplas... Urogenital Neop... Lung Neoplasm Neoplasms by Si... Papillomavirus ... Epstein-Barr Vi... Carcinoma Neoplasms Vulvar Neoplasm... Vulvar Diseases Abdominal Neopl... | STAR0602 | 18 Years - | Marengo Therapeutics, Inc. | |
| EPO906 Therapy in Patients With Advanced Colorectal Cancer | NCT00035087 | Colorectal Neop... Colonic Neoplas... | epothilone b | 18 Years - 85 Years | Novartis | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib | NCT01324596 | Lymphoma, Large... | Intravenous Bortezomib | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma | NCT00402181 | Multiple Myelom... | Siltuximab Dexamethasone | 18 Years - | Centocor, Inc. | |
| EPO906 Therapy in Patients With Advanced Kidney Cancer | NCT00035243 | Kidney Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | NCT00412321 | Lymphoma, Non-H... Multiple Myelom... Giant Lymph Nod... | CNTO 328 | 18 Years - | Centocor, Inc. | |
| A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer | NCT04630353 | HPV 16+ Confirm... | HB-201 IV HB-201 IV | 18 Years - | Hookipa Biotech GmbH | |
| A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients | NCT01320020 | Epithelial Canc... | catumaxomab | 18 Years - | Neovii Biotech | |
| EPO906 Therapy in Patients With Prostate Cancer | NCT00035113 | Prostatic Neopl... | epothilone b | 18 Years - 85 Years | Novartis | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients | NCT01320020 | Epithelial Canc... | catumaxomab | 18 Years - | Neovii Biotech | |
| A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | NCT00752518 | Refractory Multiple Myelom... Relapse | bortezomib | 20 Years - 75 Years | Janssen Pharmaceutical K.K. | |
| A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib | NCT01324596 | Lymphoma, Large... | Intravenous Bortezomib | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| EPO906 Therapy in Patients With Advanced Kidney Cancer | NCT00035243 | Kidney Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | NCT00001499 | Carcinoma, Non-... Lung Neoplasms | paclitaxel cisplatin chest radiother... | - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
